Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Ltd: Trading window closed from October 1, 2026 until 48 hours after the declaration of unaudited financial results for the quarter and half-year ended September 30, 2026.

Director appointments

• Regularization of Swanith Kapoor as Non-Executive Independent Director; term 02 Jun 2026–01 Jun 2031.
• Profile: Swanith Kapoor, qualified legal professional with LLB; not related to any director.
• Aditya Arora re-appointed as Whole Time Director; term 30 Sep 2026–29 Sep 2031; liable to retire by rotation.
• Profile: Aditya Arora, B.Com; Board since Oct 2015; oversees production, QA, regulatory filings.
• Relationships: Ajay Kumar Arora (father); Geeta Arora (mother); Ramesh Kumar (paternal uncle); Anju Arora (aunt).
• Compliance: Not debarred from holding director office.

AGM details

• AGM held on 31-08-2026; 12:00–12:35 PM; mode: VC/OAVM.
• Record date: 24-08-2026; last date for postal ballot receipt: 31-08-2026.
• Attendees via video conference: 6 promoters, 28 public.
• All resolutions passed with requisite majority.

Key resolutions

• Adopt standalone and consolidated financial statements for year ended Mar 31, 2026.
• Re-appoint Aditya Arora as Director by rotation.
• Re-appoint Anju Arora as Director by rotation.
• Appointment of Independent Director Kapoor.
• Re-appoint Aditya Arora as Whole-time Director; remuneration approved.
• Ratify Cost Auditors' remuneration.

Voting results

• Resolution 1: passed with near-unanimous support.
• Resolution 2: passed with high approval; minor opposition.
• Resolution 3: passed with high approval; minimal dissent.
• Resolution 4: passed with strong majority; some against.
• Resolution 5: passed with strong majority; small opposition.
• Resolution 6: passed with near-unanimous support; negligible dissent.

AGM Details

• Date and time: 31 August 2026, 12:00 IST.
• Mode: VC/OAVM at the registered office (deemed venue).
• Quorum: 34 members attended.

Key Resolutions

• Ordinary: Adopt standalone and consolidated financial statements for FY2025-26.
• Ordinary: Re-appoint Aditya Arora as Director (retiring by rotation).
• Ordinary: Re-appoint Anju Arora as Director (retiring by rotation).
• Special: Appoint Swanith Kapoor as Independent Director.
• Special: Re-appoint Aditya Arora as Whole Time Director; remuneration approved.
• Ordinary: Ratify Cost Auditors' remuneration.

Voting Status

• Voting results pending; Scrutinizer's report to be submitted separately.

Director Changes

• Swanith Kapoor appointed as Independent Director.
• Aditya Arora re-appointed as Director (rotating) and Whole Time Director; remuneration to be approved.
• Anju Arora re-appointed as Director (rotating).

Auditor Matters

• Cost Auditors remuneration ratified; tenure details not disclosed.

Meeting Details

• Date and Time: 10 August 2026, 4:00 PM IST.
• Type and mode: Knowledge Session (Virtual Interaction) for Investors.
• Organiser: Go India Advisors on behalf of Kwality Pharmaceuticals.
• Participants: Company management (roles not specified) presented.
• Purpose: discuss operations, performance, outlook; no UPSI shared.
• Recording: audio/video recording available; access link provided.

Operating Update

• Sixth unit (hormone) to commence by November 2026.
• Oncology share forecast 25-30% in FY27 due to registrations delays.
• Unit 5 biologicals: Erythropoietin BE pre-clinical complete; trials to start by Nov/Dec 2026.
• ROW registrations targeted in 10-12 geographies; Indian sales immediate.
• Portfolio targets 200-250 products; filings across 60-80 countries; per registration INR 1.5-2.0 million.

Guidance and Outlook

• FY27 revenue expected to cross INR 700-720 crore.
• FY28 EBITDA around 30% at INR1,000 crore revenue.
• FY29 EBITDA target around 30%.
• FY30 revenue target INR1,500 crore; growth 25-30% CAGR.
• FY29 guidance excludes biological and hormone; potential contributions in FY30.

Capex and Projects

• Bio facility: 100L CDSCO approved; 500L installed; CDSCO approval pending.
• BE programs: Ampho B liposomal and Octreotide to finish by Apr-May FY28.
• Leuprolide 45 mg first generic in 75-80% markets; submission by FY28 Q2.
• Algeria biosimilar JV: fill-finish plant; Kwality provides technology; data generation parallel.
• Biosimilar capex: INR150 crores; spend FY28 Q3 to FY29 Q4.

Auditor and Governance

• KPMG to audit; appointment expected by FY27 end.
• Q3/Q4 FY27 appointment aligns with call remarks.

Q&A Highlights

• Biological/hormone not in FY29 guidance; potential in FY30.
• BE filings expected to yield six to seven registrations per quarter.
• FY30 revenue mix: general facility about 40%; LATAM 30-35%; Europe 10-15%.
• Margins may be higher than 30% beyond FY29.

Business Overview

• Core business: injectables, beta-lactams, and complex molecules.
• In-house DSIR-recognized R&D; expanding biologics and hormone capabilities.
• Exports to 70+ markets; diversified global manufacturing and regulatory readiness.

Key Operational Highlights

• FY26 revenue was INR 503 Cr; FY27 guidance raised to 700+ Cr.
• EBITDA margin FY26 about 23.5%; FY27 guidance 27–28%.
• PAT margin FY26 about 13.4%; FY27 target ~15.5%+.
• Hormone Unit 6 capex planned at INR 65 Cr; ~50% incurred.
• First biologic Erythropoietin planned in H1 FY28.
• EU-GMP readiness: 4 of 5 plants approved; expanded regulated access.
• BE programs: 40+ solid-dose BE programs; 3+ BE studies completed in quarter.
• Working capital cycle reduced from 297 to 161 days.
• R&D headcount: 80 scientists; DSIR-recognized.
• Unit 6: hormone facility under construction; 4 of 5 units EU-GMP approved.

Financial Performance

• FY26 revenue: INR 503 Cr; FY27 guidance: 700+ Cr.
• FY26 EBITDA margin: ~23.5%; FY27 target: 27–28%.
• FY26 PAT margin: ~13.4%; FY27 target: ~15.5%+.
• Q1FY27 revenue: INR 162.4 Cr.
• Cash conversion cycle improved to 161 days; strong cash flow.
• Balance sheet: low leverage with healthy debt/coverage; capex headroom.

Capital Structure & Liquidity

• Low leverage and strong coverage; substantial headroom for capex.
• Working capital discipline driving cash generation.
• Export activities with long-cycle receivables managed through scale.

Strategic Priorities & Outlook

• Capex-led expansion across oncology, biologics, and hormones.
• Commercialize first biologic, Erythropoietin, in H1 FY28.
• EU-GMP readiness to unlock regulated markets; 4/5 plants approved.
• Licensing-driven exports to LATAM, Africa, MENA; 70+ markets.
• R&D pipeline: BE optimization and high-margin niche formulations.

Risks & Mitigation

• Regulatory approvals required; EU-GMP readiness ongoing.
• Capex execution risk; strength of balance sheet provides headroom.
• BE program outcomes critical for sustained growth.

Governance & Leadership

• Chairman & MD: Ramesh Arora; Directors: Ajay Arora, Aditya Arora.
• DSIR-recognized in-house R&D; centralized QA/QC across units.
• Audits: 20+ regulatory, customer, and vendor audits completed.

Board approvals

• Standalone and consolidated unaudited Q1 FY27 results approved; quarter ended 30 June 2026.
• Board approved results after Audit Committee review on 10 August 2026.
• Auditors' limited review reports submitted; auditors did not express an audit opinion.

Financial results and guidance

• Consolidated revenue grew 46% YoY to ₹162 crore; EBITDA ₹41 crore; PAT ₹26 crore.
• FY27 guidance raised: revenue ₹700+ crore, EBITDA ₹189-196 crore, PAT ₹109+ crore.

R&D and regulatory updates

• R&D progress: 13 BE studies completed; 15+ BE filings; 15+ product registrations across select markets.
• Biologics: Pembrolizumab pre-clinical batches approved; Erythropoietin progressed to clinical trial.
• Hormone facility on schedule; completion targeted November 2026.
• Regulatory footprint expanded across PIC/S regulators including ANVISA, SFDA, INVIMA, DIGEMID, EU-GMP.

Audit and reporting notes

• Limited audit review; results prepared under Ind AS 34 and Regulation 33 requirements.